Last €0.14 EUR
Change Today +0.005 / 3.85%
Volume 0.0
LCLA On Other Exchanges
As of 1:43 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

kalbe farma tbk pt (LCLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/15 - €0.14
52 Week Low
01/27/14 - €0.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KALBE FARMA TBK PT (LCLA)

Related News

No related news articles were found.

kalbe farma tbk pt (LCLA) Related Businessweek News

No Related Businessweek News Found

kalbe farma tbk pt (LCLA) Details

PT Kalbe Farma Tbk., together with its subsidiaries, produces and develops pharmaceutical products. The company operates in four segments: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic and branded products, and licensed drugs in the areas of antibacterial, oncology, nutrition, gastroenterology, ophthalmology, and neurology that are distributed to hospitals and pharmacies. It also offers over-the-counter drugs, supplements and other preventive products, and energy drinks and healthy ready-to-drink products; and nutritionals products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elders, as well as for consumers with special medical needs. In addition, it distributes third party pharmaceuticals products, as well as trades raw materials and medical devices; and provides retail health services. Further, the company provides animal health products; and contract research services and resources, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies. PT Kalbe Farma Tbk. was founded in 1966 and is headquartered in Jakarta, Indonesia.

12,134 Employees
Last Reported Date: 10/31/14
Founded in 1966

kalbe farma tbk pt (LCLA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kalbe farma tbk pt (LCLA) Key Developments

Kalbe Farma Provides Earnings Guidance for the Year 2014 and 2015

Kalbe Farma provided earnings guidance for the year 2014 and 2015. The company expects to post weaker-than-expected full-year 2014 sales growth of 8-9% to IDR 17.4 trillion (USD 1.39 billion), due to weaker sales of non-Kalbe products distributed by the company. This compares with sales of IDR 16 trillion in the fiscal 2013, and Kalbe's previous 2014 full-year sales growth target of 11-13% to IDR 18.08 trillion. However, sales in prescription drugs and health and nutrition products remained healthy, with the company expecting sales growth of 10%-15% in 2015. Net profit for 2014 is expected to be flat. The company has also set aside IDR 1 trillion -1.5 trillion for capital expenditure in 2015, most of which will go towards stepping up production capacities of pharmaceutical and nutrition products by 30-50%. Kalbe has also allotted IDR 150-225 billion to create 10-15 new products.

PT Kalbe Farma Tbk Presents at 7th Annual dbAccess Indonesia Conference 2014, Nov-18-2014

PT Kalbe Farma Tbk Presents at 7th Annual dbAccess Indonesia Conference 2014, Nov-18-2014 . Venue: Four Seasons, Jakarta, Indonesia.

PT Kalbe Farma Tbk Reports Earnings Results for the First Nine Months of 2014; Provides Earnings Guidance for the Full Year 2014

PT Kalbe Farma Tbk reported earnings results for the first nine months of 2014. For the period, the company reported that net sales grew by 11.5% to reach IDR 12,758 billion from IDR 11,440 billion in the same period last year. Sales growth was supported by volume growth, while price increase was effected at the end of the first quarter of 2014. Gross profit was up 10.0% to IDR 6,131 billion. The gross margin declined by 0.6% from 48.7% to 48.1%, mostly reflecting the weakening trend of Rupiah. Operating income grew by 9.0% compared to the same period last year, with a ratio of 15.7% of net sales. Net profit increased by 8.8% year-on-year. Lower net profit growth compared to sales growth was mostly attributable to contraction in gross profit margin and higher interest expense and financial charges as well as miscellaneous expenses. For full year 2014, the company maintains its revenue growth target of 11% - 13%. This lower target was attributed to weaker growth of non-Kalbe products. Operating profit margin is targeted in the range of 16.0% - 17.0%, while earnings per share is expected to grow at 11% - 13% in line with top line growth, excluding the impact of foreign exchange translation. Capital expenditure of the company is at the range of IDR 1.0 billion to IDR 1.2 billion which is mostly planned for capacity expansion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCLA:GR €0.14 EUR +0.005

LCLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LCLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation LCLA Industry Range
Price/Earnings 42.2x
Price/Sales 5.0x
Price/Book 9.8x
Price/Cash Flow 42.2x
TEV/Sales 4.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALBE FARMA TBK PT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at